author-photo

Claudia Walasek

Novartis

5

Papers

26

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

2015 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

2013 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

2013 Blood
Show All
- Source
- Cite
- Save
Citations (0)